Court decision could ban abortion pill, mifepristone, nationwide; Illinois gears up to fight mental health crisis among children; CMS rejects expanded coverage for Alzheimer drug, Leqembi.
One Texas Judge Will Determine A Nationwide Abortion Pill Ban
A decision from a Texas courtroom could ban the use of a widely used abortion pill, mifepristone from pharmacies and physician’s offices nationwide, according to Kaiser Health News. This decision, which could be decided as soon as Friday, could force the FDA to remove their approval of mifepristone, which would prevent manufacturers from shipping the drug anywhere in the United States, including states where abortion is still legal, such as California, Massachusetts, Illinois, and New York.
Illinois Gov. Addresses Child Mental Health Crisis
Governor J.B. Pritzker plans to announce on Friday efforts to provide better access and treatment to address a growing mental health crisis among children in Illinois, according to The Associated Press. This announcement will mark the start of a $22.8 million dollar proposal to tackle mental illness. Pritzker expects to implement technological, practical, legislative, and other strategies by October.
CMS Rejects Unrestricted Coverage for Alzheimer Drug
CMS rejected a request by the Alzheimer’s Association for unrestricted coverage of the drug, Leqembi. According to CNBC, the Alzheimer’s Association called the decision "appalling." CMS said it rejected the expansion on the basis of needing to see more evidence demonstrating Leqembi and similar treatments to be reasonable and necessary. CMS said it would approve expanded coverage once the drug was fully approved by the FDA; the drug was approved on an expedited basis.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More